Conversations on Health Care

The U.S. healthcare system could save up to 500,000 lives and $1.5 trillion a year by embracing the right technology, says Dr. Robert Pearl, a Stanford University professor and a noted healthcare influencer. Pearl, who co-authored his new book “ChatGPT, MD” with the help of generative AI, says the tech's strength lies in its access to the entirety of medical knowledge. “We shouldn't think of [generative AI] as just another AI tool. This is as … different from what's come before as the iPhone was from the telephone that was in most people's kitchens attached to the wall.” For clinicians and patients alike, that access can be transformative. Parents might use it to uncover what's wrong with their child when traditional medicine is still searching for answers. A doctor might identify rare diagnoses in minutes, work that would have taken days in a library. Hospitals already collect massive data — about a terabyte per facility annually — but 97% of it is never reviewed, Pearl says. The key is narrowing it to specific diseases or trends.Pearl tells “Conversations on Health Care” hosts Mark Masselli and Margaret Flinter that Gen AI will gain widespread medical acceptance when studies compare outcomes with and without the technology“We're going to find that the technology is 10% better than the average clinician … or the average nurse in a chronic disease management program…or, for that matter, potentially even the average physician doing inpatient care when there are five or six different doctors taking care of the same patient and they're not effectively communicating.”Click now to hear his take on the technology's other benefits. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Eccentric billionaire Howard Hughes founded his eponymous Medical Institute over 70 years ago devoted to “unlocking the fundamentals of biology and building an open, inclusive future for science.”Some say Howard Hughes Medical Institute is bringing its founder's vision into the future with its one-of-a-kind Janelia Research Campus in Ashburn, Virginia. On this 281-acre parcel of land, integrated teams of lab scientists and tool-builders pursue a small number of scientific questions with potential for transformative impact. To drive science forward, they share their methods, results, and tools with the scientific community.Nelson Spruston, Ph.D., the executive director at HHMI's Janelia research campus, also tells hosts Mark Masselli and Margaret Flinter about AI@HHMI, its new $500 million initiative to embed AI systems throughout every stage of the scientific process.Spruston says, “Our approach is to identify people who have a very strong track record of making important discoveries in biomedical research and letting them pursue their best ideas without asking for our permission. What we're trying to do at HHMI is to use the deep bench of talent … to come up with ideas for problems [and address] long-standing open questions in the biological sciences.” Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Roughly 85% of respondents to a survey cited by Michael Sapienza, CEO of the Colorectal Cancer Alliance, say they would rather do their taxes than get a colonoscopy. “We need to do a better job of talking to the public about the barriers,” Sapienza tells "Conversations on Health Care" hosts Mark Masselli and Margaret Flinter. Sapienza, whose mother died of the disease at age 58, says people may be less than excited to do the preparation, or colon cleanout, necessary for a screening. Or that they don't want the hassle of taking time off from work. But he emphasized that 45 is the recommended age that people begin getting regular screenings for polyps that, at some point, could develop into cancer. “45 is the new 50," says Sapienza, whose alliance was instrumental in lowering the recommended screening age and, in 2022, recruited actors Ryan Reynolds and Rob McElhenney to have their colon screenings filmed. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Roughly 85% of respondents to a survey cited by Michael Sapienza, CEO of the Colorectal Cancer Alliance, say they would rather do their taxes than get a colonoscopy.“We need to do a better job of talking to the public about the barriers,” Sapienza tells "Conversations on Health Care" hosts Mark Masselli and Margaret Flinter.Sapienza, whose mother died of the disease at age 58, says people may be less than excited to do the preparation, or colon cleanout, necessary for a screening. Or that they don't want the hassle of taking time off from work. But he emphasized that 45 is the recommended age that people begin getting regular screenings for polyps that, at some point, could develop into cancer.“45 is the new 50," says Sapienza, whose alliance was instrumental in lowering the recommended screening age and, in 2022, recruited actors Ryan Reynolds and Rob McElhenney to have their colon screenings filmed. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Two young innovators are leading a movement that proves food isn't just fuel—it's medicine. In this episode of “Conversations on Health Care,” Mark Masselli and Margaret Flinter talk with Christian Heiden, founder of Levo International, and Alissa Wassung, executive director of the Food is Medicine Coalition, about how their work is shaping the future of healthcare through food. For Heiden, hydroponic farming offers an innovative way to get fresh, nutritious food into the hands of people who need it most. “We've seen case studies where diet alone has prevented people from needing multi-million dollar surgeries,” he shares, emphasizing how access to healthier food can directly improve health outcomes. Wassung, whose coalition delivers medically tailored meals to patients with serious illnesses, highlights the broader impact. “Researchers at Tufts found that if every eligible patient received medically tailored meals, we could save $13.6 billion—with a B—in just one year,” she explains. “This is a tremendous opportunity to build a more efficient and effective healthcare system.” But this movement isn't just about numbers—it's about people. Heiden and Wassung embody a generational shift in how we view food and medicine, bringing fresh energy to solutions that could transform healthcare. Their work demonstrates that investing in food-based healthcare solutions isn't just good for patients—it's good for communities and the economy, too. Join us as we explore how hydroponic farming, medically tailored meals, and cutting-edge research are proving that the right food can prevent disease, improve outcomes, and lower healthcare costs. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Two young innovators are leading a movement that proves food isn't just fuel—it's medicine. In this episode of “Conversations on Health Care,” Mark Masselli and Margaret Flinter talk with Christian Heiden, founder of Levo International, and Alissa Wassung, executive director of the Food is Medicine Coalition, about how their work is shaping the future of healthcare through food. For Heiden, hydroponic farming offers an innovative way to get fresh, nutritious food into the hands of people who need it most. “We've seen case studies where diet alone has prevented people from needing multi-million dollar surgeries,” he shares, emphasizing how access to healthier food can directly improve health outcomes. Wassung, whose coalition delivers medically tailored meals to patients with serious illnesses, highlights the broader impact. “Researchers at Tufts found that if every eligible patient received medically tailored meals, we could save $13.6 billion—with a B—in just one year,” she explains. “This is a tremendous opportunity to build a more efficient and effective healthcare system.”But this movement isn't just about numbers—it's about people. Heiden and Wassung embody a generational shift in how we view food and medicine, bringing fresh energy to solutions that could transform healthcare. Their work demonstrates that investing in food-based healthcare solutions isn't just good for patients—it's good for communities and the economy, too.Join us as we explore how hydroponic farming, medically tailored meals, and cutting-edge research are proving that the right food can prevent disease, improve outcomes, and lower healthcare costs. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mary Bono has left the halls of Congress, but she's still winning with her efforts to stop the misuse of both prescription and illegal drugs. Bono, co-founder and chair of Mothers for Awareness and Prevention of Drug Abuse, wants to see a focus on solutions from lawmakers. With a greater presence of fentanyl in the drug supply, “everything [has] changed because there's no longer time for experimentation,” Bono says. “‘One pill can kill' is a [Drug Enforcement Administration] slogan, and it's true.” Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mary Bono has left the halls of Congress, but she's still winning with her efforts to stop the misuse of both prescription and illegal drugs. Bono, co-founder and chair of Mothers for Awareness and Prevention of Drug Abuse, wants to see a focus on solutions from lawmakers. With a greater presence of fentanyl in the drug supply, “everything [has] changed because there's no longer time for experimentation,” Bono says. “‘One pill can kill' is a [Drug Enforcement Administration] slogan, and it's true.” Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Emmy award-winning actor Michael J. Fox shocked the world when he announced over 25 years ago that he had been diagnosed with Parkinson's disease. Since then, he's devoted his talents to eliminating Parkinson's in our lifetime. Researchers with The Michael J. Fox Foundation now have impressive progress to report. They've developed a biomarker test to measure the protein alpha synuclein that's helping to diagnose Parkinson's with more than 90% accuracy, even proving effective at identifying people who may later develop the disease. “I think this is going to be a game changer for clinical trials and for patient care in the future,” says Samantha Hutten, Ph.D., a neuroscientist and vice president of translational research at the foundation. “But right now it is really a research tool that can be used to inform research and also how we design clinical trials.” A positive test, for example, may not be able to tell patients which type of alpha synuclein disease they have, whether it's Parkinson's, Lewy body dementia or multiple systems atrophy. “I think there's huge excitement around it, particularly about the impact on clinical trials,” says Rebecca Miller, Ph.D., an associate professor at Yale University's School of Medicine who was diagnosed with Parkinson's in 2013 at age 38. “We're all looking for a drug that will really be disease-modifying.” Hutten tells hosts Mark Masselli and Margaret Flinter that the biomarker test is an “all-comers” study, meaning patients can participate if they've been diagnosed or have family with Parkinson's, or have risk factors like loss of sense of smell or REM sleep behavior disorder. The test comes at a crucial time: the global rate of Parkinson's has doubled since Fox first revealed his condition. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Emmy award-winning actor Michael J. Fox shocked the world when he announced over 25 years ago that he had been diagnosed with Parkinson's disease. Since then, he's devoted his talents to eliminating Parkinson's in our lifetime.Researchers with The Michael J. Fox Foundation now have impressive progress to report. They've developed a biomarker test to measure the protein alpha synuclein that's helping to diagnose Parkinson's with more than 90% accuracy, even proving effective at identifying people who may later develop the disease.“I think this is going to be a game changer for clinical trials and for patient care in the future,” says Samantha Hutten, Ph.D., a neuroscientist and vice president of translational research at the foundation. “But right now it is really a research tool that can be used to inform research and also how we design clinical trials.”A positive test, for example, may not be able to tell patients which type of alpha synuclein disease they have, whether it's Parkinson's, Lewy body dementia or multiple systems atrophy.“I think there's huge excitement around it, particularly about the impact on clinical trials,” says Rebecca Miller, Ph.D., an associate professor at Yale University's School of Medicine who was diagnosed with Parkinson's in 2013 at age 38. “We're all looking for a drug that will really be disease-modifying.”Hutten tells hosts Mark Masselli and Margaret Flinter that the biomarker test is an “all-comers” study, meaning patients can participate if they've been diagnosed or have family with Parkinson's, or have risk factors like loss of sense of smell or REM sleep behavior disorder.The test comes at a crucial time: the global rate of Parkinson's has doubled since Fox first revealed his condition. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

About 1 in 5 colorectal patients are now under the age of 55, and colorectal cancer is now the leading cause of cancer death for men under age 50 and the second for women under 50. During Colorectal Cancer Awareness Month, we present this encore presentation of our interview with Dr. Alan Venook. Dr. Venook is with the University of California-San Francisco and is one of the nation's leading colorectal cancer researchers. He explained to “Conversations on Health Care” hosts Mark Masselli and Margaret Flinter what it will take to reverse the rise in cases among young people. Dr. Venook also talked about his research that found there's no correlation in colorectal cancer patient survival or the risk of recurrent cancer over time with less radiation—a finding that goes against conventional wisdom. Originally broadcast February 15 2024. Learn more about your ad choices. Visit podcastchoices.com/adchoices

About 1 in 5 colorectal patients are now under the age of 55, and colorectal cancer is now the leading cause of cancer death for men under age 50 and the second for women under 50.During Colorectal Cancer Awareness Month, we present this encore presentation of our interview with Dr. Alan Venook. Dr. Venook is with the University of California-San Francisco and is one of the nation's leading colorectal cancer researchers. He explained to “Conversations on Health Care” hosts Mark Masselli and Margaret Flinter what it will take to reverse the rise in cases among young people. Dr. Venook also talked about his research that found there's no correlation in colorectal cancer patient survival or the risk of recurrent cancer over time with less radiation—a finding that goes against conventional wisdom. Originally broadcast February 15 2024. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

How reliable is the current research into the cause of Alzheimer's disease? Award-winning author Charles Piller's new book is “Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's”; it's raising important questions about certain images that may have been manipulated to bolster the amyloid hypothesis as the cause of Alzheimer's. Piller tells “Conversations on Health Care” that “what you have are a multitude of images — not just in Alzheimer's disease but in many other areas — that have slipped through, that have not been well-examined, and that are, in fact, falsified, or appear to be falsified,” adding that closer scrutiny of images could spur scientists “to re-examine whether the experiments themselves are worth publishing.” Piller couches this by noting that misconduct occurs in “a small percentage” of research and “does not represent the vast bulk” of work in the field. But a greater emphasis on checks and balances is needed, he says. Hosts Mark Masselli and Margaret Flinter also ask Piller to respond to criticism of his reporting as well as explain other potential sources of hope in the research field. For instance, clinical trials may reveal, as early as next year, the possible impact of GLP-1 inhibitors — medications developed for obesity and diabetes — on Alzheimer's. Another theory examines the effect of latent viruses, such as herpes, on the brain. Learn more about your ad choices. Visit podcastchoices.com/adchoices

How reliable is the current research into the cause of Alzheimer's disease? Award-winning author Charles Piller's new book is “Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's”; it's raising important questions about certain images that may have been manipulated to bolster the amyloid hypothesis as the cause of Alzheimer's. Piller tells “Conversations on Health Care” that “what you have are a multitude of images — not just in Alzheimer's disease but in many other areas — that have slipped through, that have not been well-examined, and that are, in fact, falsified, or appear to be falsified,” adding that closer scrutiny of images could spur scientists “to re-examine whether the experiments themselves are worth publishing.” Piller couches this by noting that misconduct occurs in “a small percentage” of research and “does not represent the vast bulk” of work in the field. But a greater emphasis on checks and balances is needed, he says. Hosts Mark Masselli and Margaret Flinter also ask Piller to respond to criticism of his reporting as well as explain other potential sources of hope in the research field. For instance, clinical trials may reveal, as early as next year, the possible impact of GLP-1 inhibitors — medications developed for obesity and diabetes — on Alzheimer's. Another theory examines the effect of latent viruses, such as herpes, on the brain. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Louis Sullivan walked the halls of Congress and testified before committees when he was secretary of the U.S. Department of Health and Human Services. That experience, working in a bipartisan fashion in the President George H.W. Bush administration, is valuable now. During Black History Month, we revisit our interview with Dr. Sullivan for lessons about leadership and the challenges that still exist in our healthcare system. Dr. Sullivan advocates for more Blacks to train to become doctors and explains the challenges that still exist for them joining the profession. Listen in as hosts Mark Masselli and Margaret Flinter ask him to share his insights. Originally broadcast January, 2023. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Louis Sullivan walked the halls of Congress and testified before committees when he was secretary of the U.S. Department of Health and Human Services. That experience, working in a bipartisan fashion in the President George H.W. Bush administration, is valuable now. During Black History Month, we revisit our interview with Dr. Sullivan for lessons about leadership and the challenges that still exist in our healthcare system. Dr. Sullivan advocates for more Blacks to train to become doctors and explains the challenges that still exist for them joining the profession. Listen in as hosts Mark Masselli and Margaret Flinter ask him to share his insights.Originally broadcast January, 2023. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Artificial intelligence is revolutionizing health care—but how do we ensure it's safe, effective, and responsible? Dr. Brian Anderson, CEO of the Coalition for Health AI (CHAI), explains to “Conversations on Health Care” how his organization is working to establish clear guidelines for responsible AI in health care. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Artificial intelligence is revolutionizing health care—but how do we ensure it's safe, effective, and responsible? Dr. Brian Anderson, CEO of the Coalition for Health AI (CHAI), explains to “Conversations on Health Care” how his organization is working to establish clear guidelines for responsible AI in health care. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

$4.95 — that's the record high price of a dozen of Grade A eggs in U.S. cities. Michael Osterholm, Ph.D., the director of the Center for Infectious Disease Research and Policy, says expect them to go even higher. That's because H5N1, a form of bird flu, has affected more than 156 million commercial, backyard and wild birds in the United States in the last three years. Osterholm, with nearly 50 years of experience investigating infectious disease outbreaks, emphasizes the urgent need for improved pandemic preparedness. “It's not a question of if, but when the next major outbreak will happen. Whether it's a more contagious strain of COVID-19, the bird flu or a completely new virus, we need systems in place now to protect public health and save lives.” He joins Apoorva Mandavilli, the science and global health reporter with The New York Times, to explore the critical lessons learned from COVID-19 and what must be done to prepare for future public health threats. “Bird flu may seem like a distant problem, but the global nature of infectious diseases means we're all connected,” Mandavilli says. She also notes that public trust plays a crucial role in mitigating future pandemics. “Without transparency and clear communication, public health measures are far less effective.” Conversations on Health Care hosts Mark Masselli and Margaret Flinter also ask them how public health agencies must adapt, improve transparency and build global cooperation to combat future outbreaks. Learn more about your ad choices. Visit podcastchoices.com/adchoices

$4.95 — that's the record high price of a dozen of Grade A eggs in U.S. cities. Michael Osterholm, Ph.D., the director of the Center for Infectious Disease Research and Policy, says expect them to go even higher.That's because H5N1, a form of bird flu, has affected more than 156 million commercial, backyard and wild birds in the United States in the last three years. Osterholm, with nearly 50 years of experience investigating infectious disease outbreaks, emphasizes the urgent need for improved pandemic preparedness. “It's not a question of if, but when the next major outbreak will happen. Whether it's a more contagious strain of COVID-19, the bird flu or a completely new virus, we need systems in place now to protect public health and save lives.”He joins Apoorva Mandavilli, the science and global health reporter with The New York Times, to explore the critical lessons learned from COVID-19 and what must be done to prepare for future public health threats. “Bird flu may seem like a distant problem, but the global nature of infectious diseases means we're all connected,” Mandavilli says. She also notes that public trust plays a crucial role in mitigating future pandemics. “Without transparency and clear communication, public health measures are far less effective.”Conversations on Health Care hosts Mark Masselli and Margaret Flinter also ask them how public health agencies must adapt, improve transparency and build global cooperation to combat future outbreaks. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Noted healthcare leader Dr. Sachin Jain has been publicly releasing his annual predictions for the sector for five years and is proud of his “pretty accurate” track record. He's out now with his list of top 10 predictions for the healthcare industry for 2025. Dr. Jain states that “Heretofore fringe ideas about wellness and disease causation and medications will continue to go mainstream.” Dr. Jain has held top positions at the Centers for Medicare and Medicaid Services and the Office of the National Coordinator for Health IT. More recently, he's been a leader in the nonprofit health world, so he has a unique perspective on the entire field. Listen in as he discusses his ideas with “Conversations on Health Care” hosts Mark Masselli and Margaret Flinter. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Noted healthcare leader Dr. Sachin Jain has been publicly releasing his annual predictions for the sector for five years and is proud of his “pretty accurate” track record. He's out now with his list of top 10 predictions for the healthcare industry for 2025. Dr. Jain states that “Heretofore fringe ideas about wellness and disease causation and medications will continue to go mainstream.”Dr. Jain has held top positions at the Centers for Medicare and Medicaid Services and the Office of the National Coordinator for Health IT. More recently, he's been a leader in the nonprofit health world, so he has a unique perspective on the entire field. Listen in as he discusses his ideas with “Conversations on Health Care” hosts Mark Masselli and Margaret Flinter. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

President Trump's first days in office have resulted in a number of important changes in the healthcare landscape. President Trump has withdrawn the United States from the World Health Organization, rolled back drug pricing policies and limited gender-affirming care. In addition, Robert F. Kennedy, Jr., awaits his confirmation hearing to serve as secretary of the U.S. Dept. of Health and Human Services. Conversations on Health Care hosts Mark Masselli and Margaret Flinter are bringing together leading healthcare journalists to discuss the new administration's moves and what they mean. Their guests this week are: Shannon Firth with MedPage Today Michael McAuliff with Modern Healthcare; and  Sarah Owermohle with STAT. Learn more about your ad choices. Visit podcastchoices.com/adchoices

President Trump's first days in office have resulted in a number of important changes in the healthcare landscape. President Trump has withdrawn the United States from the World Health Organization, rolled back drug pricing policies and limited gender-affirming care. In addition, Robert F. Kennedy, Jr., awaits his confirmation hearing to serve as secretary of the U.S. Dept. of Health and Human Services. Conversations on Health Care hosts Mark Masselli and Margaret Flinter are bringing together leading healthcare journalists to discuss the new administration's moves and what they mean. Their guests this week are: Shannon Firth with MedPage Today Michael McAuliff with Modern Healthcare; and  Sarah Owermohle with STAT. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

As the year begins, some patients remain concerned about how far artificial intelligence (AI) is creeping into the exam room. But AI has been part of health care longer than most realize, according to Dr. Isaac Kohane, a Harvard University professor. Kohane is the editor-in-chief of the New England Journal of Medicine's first publication devoted to AI; it's a groundbreaking role and we're proud to share an encore presentation of the interview. He told hosts Mark Masselli and Margaret Flinter that “In the 1980s, automated interpretation of an [echocardiogram] would have been considered AI. Now it's the ability to look through a patient's record and come up with a differential diagnosis, a second opinion, a therapeutic plan.” Kohane shared a success story of a mother whose child had difficulty walking and chewing, suffered from headaches and had seen more than a dozen doctors over many years, with no diagnosis. After one doctor recommended a psychiatric course of action, the mother fed the reports from various past medical visits into a generative AI program, which provided an accurate diagnosis: tethered cord syndrome. Cases like this can represent AI's potential, said Kohane. But the nascent technology raises issues of bias. “You can run tests on these AI programs and say, ‘Would you propose that diagnosis more often if this was an African-American or an Indian-American?' … And you can adjust these programs,” Kohane says. The exciting part is that the adjustment would be easier than undoing even unconscious bias among hundreds of thousands of health care professionals, he explained. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

As the year begins, some patients remain concerned about how far artificial intelligence (AI) is creeping into the exam room. But AI has been part of health care longer than most realize, according to Dr. Isaac Kohane, a Harvard University professor. Kohane is the editor-in-chief of the New England Journal of Medicine's first publication devoted to AI; it's a groundbreaking role and we're proud to share an encore presentation of the interview. He told hosts Mark Masselli and Margaret Flinter that “In the 1980s, automated interpretation of an [echocardiogram] would have been considered AI. Now it's the ability to look through a patient's record and come up with a differential diagnosis, a second opinion, a therapeutic plan.” Kohane shared a success story of a mother whose child had difficulty walking and chewing, suffered from headaches and had seen more than a dozen doctors over many years, with no diagnosis. After one doctor recommended a psychiatric course of action, the mother fed the reports from various past medical visits into a generative AI program, which provided an accurate diagnosis: tethered cord syndrome. Cases like this can represent AI's potential, said Kohane. But the nascent technology raises issues of bias. “You can run tests on these AI programs and say, ‘Would you propose that diagnosis more often if this was an African-American or an Indian-American?' … And you can adjust these programs,” Kohane says. The exciting part is that the adjustment would be easier than undoing even unconscious bias among hundreds of thousands of health care professionals, he explained. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The World Health Organization has issued a statement expressing concern about artificial intelligence in health care. In 2023, Mayo Clinic's then-Chief Information Officer Cris Ross joined us to discuss it. He led innovation projects at Mayo Clinic for over 30 years and told us “perhaps” we should be worried about ChatGPT. “These technologies are value-neutral but their usage is not necessarily value-neutral. Bad people can use good technology for bad purposes. So I think there's a very robust debate about whether these technologies should be regulated, whether they can be regulated, and if they are regulated, how we should do that,” Ross told us at the time. Listen in on this encore presentation as Ross takes hosts Mark Masselli and Margaret Flinter through this brave new world that promises to affect every part of health care. Originally broadcast June 8, 2023. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The World Health Organization has issued a statement expressing concern about artificial intelligence in health care. In 2023, Mayo Clinic's then-Chief Information Officer Cris Ross joined us to discuss it. He led innovation projects at Mayo Clinic for over 30 years and told us “perhaps” we should be worried about ChatGPT. “These technologies are value-neutral but their usage is not necessarily value-neutral. Bad people can use good technology for bad purposes. So I think there's a very robust debate about whether these technologies should be regulated, whether they can be regulated, and if they are regulated, how we should do that,” Ross told us at the time. Listen in on this encore presentation as Ross takes hosts Mark Masselli and Margaret Flinter through this brave new world that promises to affect every part of health care. Originally broadcast June 8, 2023. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Conversations on Health Care hopes the new year is off to a great start for you! But before we completely turn the page on 2024, we want to look back on our top issues and interviews from the past year. We spoke to leading experts about the health care policies that were part of the presidential race; the promise and peril of artificial intelligence; the research into happiness; and many other issues. As President Trump, a new Congress and other new leaders in the states prepare for office, hosts Mark Masselli and Margaret Flinter present this recap and look ahead to the ideas, innovations and insights driving health care. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Conversations on Health Care hopes the new year is off to a great start for you! But before we completely turn the page on 2024, we want to look back on our top issues and interviews from the past year. We spoke to leading experts about the health care policies that were part of the presidential race; the promise and peril of artificial intelligence; the research into happiness; and many other issues.As President Trump, a new Congress and other new leaders in the states prepare for office, hosts Mark Masselli and Margaret Flinter present this recap and look ahead to the ideas, innovations and insights driving health care. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Amit Sood is called the “Happiness Doctor” for a good reason; his resilience approach has been included in over 35 clinical trials. The holiday season, occurring right after an intense election, is an ideal time to learn from Dr. Sood about how to recognize stress and reprogram the brain to deal with it. One of his top pieces of advice: Ask yourself if what is upsetting you will matter in five years? If the answer is no, let it go. Dr. Sood is the CEO of Global Center for Resiliency and Wellbeing, the former chair of Student Life and Wellness at Mayo Clinic, and the author of the new book “ “It Takes You to Tango: Leverage the Science of Loneliness to Master the Art of Connection.” Join Mark Masselli and Margaret Flinter for this insightful conversation that will help us all navigate negative thinking. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Amit Sood is called the “Happiness Doctor” for a good reason; his resilience approach has been included in over 35 clinical trials. The holiday season, occurring right after an intense election, is an ideal time to learn from Dr. Sood about how to recognize stress and reprogram the brain to deal with it. One of his top pieces of advice: Ask yourself if what is upsetting you will matter in five years? If the answer is no, let it go.Dr. Sood is the CEO of Global Center for Resiliency and Wellbeing, the former chair of Student Life and Wellness at Mayo Clinic, and the author of the new book “ “It Takes You to Tango: Leverage the Science of Loneliness to Master the Art of Connection.” Join Mark Masselli and Margaret Flinter for this insightful conversation that will help us all navigate negative thinking. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Billionaires who dream of extending human life, including Elon Musk, believe they will have very supportive partners in the incoming Trump administration. They're excited that President Trump has nominated Jim O'Neill for the number two spot at the U.S. Dept. of Health and Human Services because of his history in the anti-aging movement. David Gobel, the co-founder and CEO of the Methuselah Fund, says, “Jim O'Neill really understands the value of avoiding the suffering…of diseases that don't actually have to happen if aging is held back. Robert F. Kennedy, Jr., and other nominees are very much in line with the idea of holding aging back by whatever means.” President Trump has nominated Kennedy to serve as HHS secretary. But “Conversations on Health Care” recently spoke with S. Jay Olshansky, Ph.D., a professor at the University of Illinois at Chicago, who questioned private and public dollars going to such efforts. “We'll be lucky if 5% of the age cohort makes it to 100,” he said. Olshansky and his colleagues have presented data that humans are approaching a biologically-based limit to life. Join hosts Mark Masselli and Margaret Flinter for this look into the world of life extension and how Trump administration officials could push the country to embrace these unconventional practices. In addition, learn more about the first longevity patient protocol from Danielle Ruiz, MSN, APRN, AGNP-C, CEO and Medical Director, Everest Health. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Billionaires who dream of extending human life, including Elon Musk, believe they will have very supportive partners in the incoming Trump administration. They're excited that President Trump has nominated Jim O'Neill for the number two spot at the U.S. Dept. of Health and Human Services because of his history in the anti-aging movement.David Gobel, the co-founder and CEO of the Methuselah Fund, says, “Jim O'Neill really understands the value of avoiding the suffering…of diseases that don't actually have to happen if aging is held back. Robert F. Kennedy, Jr., and other nominees are very much in line with the idea of holding aging back by whatever means.” President Trump has nominated Kennedy to serve as HHS secretary.But “Conversations on Health Care” recently spoke with S. Jay Olshansky, Ph.D., a professor at the University of Illinois at Chicago, who questioned private and public dollars going to such efforts. “We'll be lucky if 5% of the age cohort makes it to 100,” he said. Olshansky and his colleagues have presented data that humans are approaching a biologically-based limit to life.Join hosts Mark Masselli and Margaret Flinter for this look into the world of life extension and how Trump administration officials could push the country to embrace these unconventional practices. In addition, learn more about the first longevity patient protocol from Danielle Ruiz, MSN, APRN, AGNP-C, CEO and Medical Director, Everest Health. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nurse practitioners, at 385,000 strong in the U.S., are increasingly seen as a key part of the solution to the primary care provider shortage. What are the challenges and opportunities to ensure everyone can get the care they need when they need it? Our guest is the president of the American Association of Nurse Practitioners, Stephen Ferrara, DNP. He also serves as the inaugural associate dean of artificial intelligence and a professor of nursing at the Columbia University School of Nursing. Hosts Mark Masselli and Margaret Flinter (who has been a family nurse practitioner for many years) discuss the opportunities for Ferrara and his members as they seek to expand what's called “scope of practice.” In fact, the percentage of medical visits handled by health care providers other than physicians nearly doubled between 2013 and 2019, with many of those patients seen by nurse practitioners. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nurse practitioners, at 385,000 strong in the U.S., are increasingly seen as a key part of the solution to the primary care provider shortage. What are the challenges and opportunities to ensure everyone can get the care they need when they need it? Our guest is the president of the American Association of Nurse Practitioners, Stephen Ferrara, DNP. He also serves as the inaugural associate dean of artificial intelligence and a professor of nursing at the Columbia University School of Nursing.Hosts Mark Masselli and Margaret Flinter (who has been a family nurse practitioner for many years) discuss the opportunities for Ferrara and his members as they seek to expand what's called “scope of practice.” In fact, the percentage of medical visits handled by health care providers other than physicians nearly doubled between 2013 and 2019, with many of those patients seen by nurse practitioners. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

HIV/AIDS experts are cautiously watching as President Trump and his administration near inauguration day. On one hand, they remember how President Trump announced in 2019 his initiative called Ending the HIV Epidemic: A Plan for America. It included Ready, Set, PrEP, a U.S. Department of Health and Human Services initiative that provides free access to the HIV prevention medication PrEP for thousands of qualifying individuals. But there are worries “about the next four years because we're hearing about a potential decrease in funding,” that will be detrimental to programs, according to Dr. Marwan Haddad, Medical Director of the Center for Key Populations, Community Health Center, Inc., and a former chair of the HIV Medicine Association. Vincent Guilamo-Ramos, Ph.D., MPH, Executive Director, Institute for Policy Solutions at the Johns Hopkins School of Nursing, highlighted these issues as communities recognized World AIDS Day on Dec. 1. For instance, the CDC reports new HIV infections fell by 19% from 2018 to 2022 but there's been a 12% increase in infections among Latino people. Our guests join hosts Mark Masselli and Margaret Flinter to discuss progress and the hurdles that still exist in the fight to end AIDS. Learn more about your ad choices. Visit podcastchoices.com/adchoices

HIV/AIDS experts are cautiously watching as President Trump and his administration near inauguration day. On one hand, they remember how President Trump announced in 2019 his initiative called Ending the HIV Epidemic: A Plan for America. It included Ready, Set, PrEP, a U.S. Department of Health and Human Services initiative that provides free access to the HIV prevention medication PrEP for thousands of qualifying individuals.But there are worries “about the next four years because we're hearing about a potential decrease in funding,” that will be detrimental to programs, according to Dr. Marwan Haddad, Medical Director of the Center for Key Populations, Community Health Center, Inc., and a former chair of the HIV Medicine Association. Vincent Guilamo-Ramos, Ph.D., MPH, Executive Director, Institute for Policy Solutions at the Johns Hopkins School of Nursing, highlighted these issues as communities recognized World AIDS Day on Dec. 1. For instance, the CDC reports new HIV infections fell by 19% from 2018 to 2022 but there's been a 12% increase in infections among Latino people.Our guests join hosts Mark Masselli and Margaret Flinter to discuss progress and the hurdles that still exist in the fight to end AIDS. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Amit Sood is called the “Happiness Doctor” for a good reason; his resilience approach has been included in over 35 clinical trials. The holiday season, occurring right after an intense election, is an ideal time to learn from Dr. Sood about how to recognize stress and reprogram the brain to deal with it. One of his top pieces of advice: Ask yourself if what is upsetting you will matter in five years? If the answer is no, let it go. Dr. Sood is the CEO of Global Center for Resiliency and Wellbeing, the former chair of Student Life and Wellness at Mayo Clinic, and the author of the new book “It Takes You to Tango: Leverage the Science of Loneliness to Master the Art of Connection.” Join Mark Masselli and Margaret Flinter for this insightful conversation that will help us all navigate negative thinking. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Amit Sood is called the “Happiness Doctor” for a good reason; his resilience approach has been included in over 35 clinical trials. The holiday season, occurring right after an intense election, is an ideal time to learn from Dr. Sood about how to recognize stress and reprogram the brain to deal with it. One of his top pieces of advice: Ask yourself if what is upsetting you will matter in five years? If the answer is no, let it go.Dr. Sood is the CEO of Global Center for Resiliency and Wellbeing, the former chair of Student Life and Wellness at Mayo Clinic, and the author of the new book “It Takes You to Tango: Leverage the Science of Loneliness to Master the Art of Connection.” Join Mark Masselli and Margaret Flinter for this insightful conversation that will help us all navigate negative thinking. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

TV ads focused on health care issues — including transgender care, abortion and costs — ricocheted across the airwaves in the months leading up to election day. Erika Franklin Fowler, Ph.D., is a co-director of the Wesleyan Media Project, which tracks political ads. She joins “Conversations on Health Care” to discuss a controversial anti-transgender surgery ad from the Republicans that also benefited from free media attention, as well as House and Senate candidates picking up on similar themes in their advertising. Preliminary numbers show $4.5 billion was spent on political TV and radio ads this year. These ads and their messages reflect the goals of President Trump and his new administration as they plan a return to power in the nation's capital. Hosts Mark Masselli and Margaret Flinter discuss the TV ad wars and their implications for health care policy with Dr. Franklin Fowler.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

TV ads focused on health care issues — including transgender care, abortion and costs — ricocheted across the airwaves in the months leading up to election day. Erika Franklin Fowler, Ph.D., is a co-director of the Wesleyan Media Project, which tracks political ads. She joins “Conversations on Health Care” to discuss a controversial anti-transgender surgery ad from the Republicans that also benefited from free media attention, as well as House and Senate candidates picking up on similar themes in their advertising. Preliminary numbers show $4.5 billion was spent on political TV and radio ads this year. These ads and their messages reflect the goals of President Trump and his new administration as they plan a return to power in the nation's capital. Hosts Mark Masselli and Margaret Flinter discuss the TV ad wars and their implications for health care policy with Dr. Franklin Fowler.  Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.